Provided by Tiger Fintech (Singapore) Pte. Ltd.

COLLPLANT BIOTECHNOLOGIES LTD

2.29
-0.1295-5.35%
Post-market: 2.26-0.0305-1.33%19:53 EDT
Volume:20.62K
Turnover:48.89K
Market Cap:29.13M
PE:-1.89
High:2.50
Open:2.37
Low:2.22
Close:2.42
Loading ...

Collplant Biotechnologies Ltd expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
29 Jul

Collplant Biotechnologies Ltd expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
15 Jul

CollPlant Biotechnologies Appoints Bowman Bagley as VP of North America Commercial Operations to Drive Growth and Expansion

Reuters
·
14 Jul

Press Release: CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations

Dow Jones
·
14 Jul

CollPlant Biotechnologies Expands Partnership with STEMCELL Technologies for Clinical and Commercial Applications

Reuters
·
09 Jun

CollPlant Biotechnologies Secures European Patent for Innovative Collagen-Based Soft Tissue Fillers and Implants

Reuters
·
04 Jun

Top Premarket Decliners

MT Newswires Live
·
30 May

CollPlant Biotechnologies Ltd. Announces $3.6 Million Share Issue in Registered Direct Offering

Reuters
·
30 May

Collplant Biotechnologies Is Maintained at Buy by D. Boral Capital

Dow Jones
·
28 May

CollPlant Biotechnologies Q1 2025 Adj. EPS $(0.10) Misses $(0.04) Estimate, Sales $2.06M Miss $2.65M Estimate

Benzinga
·
28 May

CollPlant Biotechnologies Reports Q1 Surge in Revenues to $2.055M, Reduces Net Loss to $1.452M, EPS Improves to $0.13

Reuters
·
28 May

Press Release: COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

Dow Jones
·
28 May

Collplant Biotechnologies Ltd expected to post a loss of 4 cents a share - Earnings Preview

Reuters
·
26 May

CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies

PR Newswire
·
15 Apr

When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven?

Simply Wall St.
·
28 Mar

Collplant Biotechnologies Is Maintained at Buy by D. Boral Capital

Dow Jones
·
27 Mar

CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

GuruFocus.com
·
27 Mar

CollPlant Biotechnologies FY 2024 GAAP EPS $(1.45) Misses $(1.44) Estimate, Sales $515.000K Miss $1.640M Estimate

Benzinga
·
26 Mar

Press Release: COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

Dow Jones
·
26 Mar

Collplant Biotechnologies Ltd expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
24 Mar